SPI Infoamtion

このレポートは章ごとの個別販売も行っておりますのでお問い合わせ下さい。
※全てPDFでの販売となります。

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES
REASONS FOR STUDY
SCOPE OF STUDY
METHODOLOGY AND INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
DISCLAIMER

Chapter-2: EXECUTIVE SUMMARY

EXECUTIVE SUMMARY
SMMARY TABLE TOTAL MARKET FOR DEPRESSIVE AND ANXIETY DISORDERS, THROUGH 2014 ($ MILLIONS)
SUMMARY FIGURE TOTAL MARKET FOR DEPRESSIVE AND ANXIETY DISORDERS, 2007-2014 ($ MILLIONS)

Chapter-3: INDUSTRY OVERVIEW

HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY
INTRODUCTION TO THE NERVOUS SYSTEM AND BRAIN
BLOOD-BRAIN BARRIER
DEMOGRAPHICS
TABLE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL REGION, 2008--2050 (MILLIONS)
FIGURE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL REGION, 2008--2050 (MILLIONS)
TABLE 2 ESTIMATED WORLD POPULATION BY AGE AND GEOGRAPHICAL REGION, 2008 (MILLIONS)
FIGURE 2 ESTIMATED WORLD POPULATION BY AGE AND GEOGRAPHICAL REGION, 2008 (MILLIONS)
TABLE 3 POPULATION OVER 65 BY YEAR AND REGION, 2008-2050 (%)
FIGURE 3 POPULATION OVER 65 BY YEAR AND REGION, 2008-2050
PREVALENCE OF MENTAL DISORDERS
TABLE 4 BEST ESTIMATE 1-YEAR PREVALENCE RATES BASED ON ECA AND NCS, AGES 18-54 (%)
TABLE 5 PERCENTAGE OF INDIVIDUALS 12 YEARS AND OLDER WITH DEPRESSION BY DEMOGRAPHIC CHARACTERISTIC―AGE, SEX, AND RACE, U.S. 2006 (%)
TABLE 6 PERCENTAGE OF INDIVIDUALS WITH DEPRESSION BY AGE AND POVERTY STATUS, UNITED STATES 2006 (%)
TABLE 7 INDIVIDUALS 12 YEAR OF AGE AND OLDER REPORTING DIFFICULTY WITH THEIR WORK, HOME, AND SOCIAL ACTIVITIES BY SEX AND DEPRESSION SEVERITY, UNITED STATES, 2006 (%)
TABLE 8 INDIVIDUALS 12 YEARS OF AGE AND OLDER CONTACTING A MENTAL HEALTH PROFESSIONAL IN THE PAST 12 MONTHS, BY DEPRESSION SEVERITY, UNITED STATES 2006 (%)
CHILDREN AND ADOLESCENTS
OLDER ADULTS
COSTS OF MENTAL ILLNESS
TABLE 9 BEST ESTIMATE PREVALENCE RATES BASED ON EPIDEMIOLOGICAL CATCHMENT AREA, AGE 55+ (%)
DEPRESSIVE DISORDERS
MAJOR DEPRESSION
Etiology and Neurobiology
TABLE 10 RISK FACTORS FOR MAJOR DEPRESSIVE AND BIPOLAR DISORDERS
TABLE 11 PREFRONTAL CORTEX AND SEROTONIN INTERCONNECTIONS: IMPLICATIONS IN DEPRESSION
Clinical Manifestations
BIPOLAR DISORDER
Etiology and Neurobiology
Clinical Manifestations
Bipolar I Disorder
Bipolar II Disorder
SEASONAL AFFECTIVE DISORDER
Clinical Manifestations
ANXIETY DISORDERS
Panic Disorder
Etiology and Neurobiology
Clinical Manifestations
Generalized Anxiety Disorder
Etiology and Neurobiology
Clinical Manifestations
Obsessive-Compulsive Disorder
Etiology and Neurobiology
Clinical Manifestations
Specific and Social Phobias
TABLE 12 CLINICAL NAMES FOR COMMON PHOBIAS
Post-Traumatic Stress Disorder
GENERIC INFLUENCE
ELDERLY IMPACT
DEPRESSION
ANXIETY
CHILDREN AND ADOLESCENT IMPACT
DEPRESSION
Symptoms of Depression in Children
ANXIETY
ALTERNATIVE AND COMPLEMENTARY THERAPIES
ST. JOHN’S WORT (HYPERFORIN AND HYPERICIN)
VALERIAN ROOT
5-HTP
RHODIOLA ROSEA
SAM-E
BACOPA
GINSENG
B VITAMINS - B1, B3, B5, B6, B9, AND B12
ZINC
MAGNESIUM
KAVA KAVA
OVERUSE OF ANTIDEPRESSANTS―ANOTHER VIEW
LEGISLATIVE ISSUES
COMPLIANCE ISSUES
PRESCRIBING TRENDS
DEPRESSION RISK DUE TO BRAIN THINNING
SUICIDAL BEHAVIOR AND ANTIDEPRESSANTS
NOVEL APPROACH IN TEEN SUICIDE
COMBINATION THERAPY
REMOTE SUPPORT FOR DEPRESSION
TREATMENTS AND PRODUCTS FOR DEPRESSIVE DISORDERS
PRESCRIPTION PRODUCTS
Selective Serotonin Reuptake Inhibitors
Side Effects
Pharmacologics
Serotonin-Norepinephrine Reuptake Inhibitors
Tricyclic Antidepressants
Chemical Aspects
Mechanism of Action
Actions and Side Effects
Pharmacologics
Monoamine Inhibitors
Chemical Aspects
Pharmacologics
Side Effects
Others
Marketed Antidepressants
TABLE 13 SELECTED MARKETED ANTIDEPRESSANT DRUGS ($ MILLIONS)
ALTERNATIVE TREATMENTS
Light Therapy
Electroconvulsive Therapy
Acupressure
Acupuncture
Biofeedback
Nutrition
Reflexology
Self-Help Groups
Animal-Assisted Therapies
Expressive Therapies
Art Therapy
Dance/Movement Therapy
Music/Sound Therapy
Guided Imagery or Visualization
Massage Therapy
Technology-Based Applications
Telemedicine
Telephone Counseling
Electronic Communications
Radio Psychiatry
Vagus Nerve Stimulation (VNS)
Transcranial Magnetic Stimulation (TMS)
Deep Brain Stimulation
TREATMENTS AND PRODUCTS FOR ANXIETY DISORDERS
PRESCRIPTION PRODUCTS
Barbiturates
Benzodiazepines
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Effexor
Cymbalta
Antihistamines
Anticonvulsants/Bipolar
Lamictal
Lithium
Beta-Blockers
Antipsychotics
Abilify
BuSpar
Geodon
Risperdal
Seroquel
Zyprexa
TABLE 14 SELECTED MARKETEDANTIANXIETY DRUGS

Chapter-4: MARKET SIZE AND GROWTH

TOTAL MARKET
Total Antidepressant and Antianxiety Drug Market by Product Classification
TABLE 15 TOTAL MARKET FOR DEPRESSIVE AND ANXIETY DISORDERS, THROUGH 2014 ($ MILLIONS)
FIGURE 4 TOTAL MARKET FOR DEPRESSIVE AND ANXIETY DISORDERS, 2007-2014 ($ MILLIONS)
TABLE 16 TOTAL MARKET SHARE BY CATEGORY, 2009 AND 2014 (%)
FIGURE 5 TOTAL MARKET SHARE BY CATEGORY, 2009 AND 2014 (%)
TOTAL ANTIDEPRESSANT AND ANTIANXIETY DRUG MARKET BY GEOGRAPHIC SEGMENTS
FIGURE 6 GLOBAL MARKET SIZE OF THERAPIES FOR DEPRESSIVE AND ANXIETY DISORDERS BY REGION, 2007-2014 ($ MILLIONS)
TABLE 18 TOTAL MARKET SHARE BY REGION, 2009 AND 2014 (%)
FIGURE 7 TOTAL MARKET SHARE BY REGION, 2009 AND 2014 (%)
DEPRESSION MARKET
ANTIDEPRESSANT DRUG MARKET BY PRODUCT CLASSIFICATION
TABLE 19 GLOBAL MARKET FOR ANTIDEPRESSANTS BY PRODUCT, THROUGH 2014 ($ MILLIONS)
FIGURE 8 GLOBAL MARKET FOR ANTIDEPRESSANTS BY PRODUCT, 2007-2014 ($ MILLIONS)
TABLE 20 GLOBAL MARKET SHARE OF ANTIDEPRESSANTS BY PRODUCT, THROUGH 2014 (%)
FIGURE 9 GLOBAL MARKET SHARE OF ANTIDEPRESSANTS BY PRODUCT, 2007-2014 (%)
ANTIDEPRESSANT DRUG MARKET BY GEOGRAPHIC SEGMENTS
United States
European Union
Japan
Rest of World
TABLE 21 GLOBAL MARKET FOR ANTIDEPRESSANTS BY REGION, 2007-2014 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET FOR ANTIDEPRESSANTS BY REGION, 2007-2014 ($ MILLIONS)
TABLE 22 GLOBAL MARKET SHARE OF GLOBAL ANTIDEPRESSANTS BY REGION, 2007-2014 (%)
FIGURE 11 GLOBAL MARKET SHARE OF GLOBAL ANTIDEPRESSANTS BY REGION, 2007-2014 (%)
ANTIANXIETY MARKET
ANTIANXIETY DRUG MARKET BY PRODUCT CLASSIFICATION
TABLE 23 GLOBAL MARKET FOR ANTIANXIETY DRUGS BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS)
TABLE 24 GLOBAL MARKET SHARE OF ANTIANXIETY DRUGS BY PRODUCT TYPE, 2007-2014 (%)
FIGURE 12 GLOBAL MARKET FOR ANTIANXIETY DRUGS BY PRODUCT TYPE, 2007-2014 ($ MILLIONS)
FIGURE 13 GLOBAL MARKET SHARE OF ANTIANXIETY DRUGS BY PRODUCT TYPE, 2007-2014 (%)
ANTIANXIETY DRUG MARKET BY GEOGRAPHIC SEGMENTS
United States
European Union
Japan
Rest of World
TABLE 25 GLOBAL MARKET SIZE OF ANTIANXIETY DRUGS BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET SIZE OF ANTIANXIETY DRUGS BY REGION, 2007-2014 ($ MILLIONS)
TABLE 26 GLOBAL MARKET SHARE OF GLOBAL ANTIANXIETY DRUGS BY REGION, 2007-2014 (%)
FIGURE 15 GLOBAL MARKET SHARE OF GLOBAL ANTIANXIETY DRUGS BY REGION, 2007-2014 (%)

Chapter-5: RESEARCH AND DEVELOPMENT

GEODON
GEPIRONE ER
RISPERDAL CONSTA
SAPHRIS
SEROQUEL XR
TRAZODONE ONCE DAILY
AGI0178
CORLUX
INVEGA
LU AA21004
LYRICA
NUVIGIL
SAREDUTANT
VILAZODONE
TABLE 27 THERAPIES IN DEVELOPMENT FOR DEPRESSION AND ANXIETY, 2009
NOVEL PRODUCTS IN DEVELOPMENT

Chapter-6: COMPETITIVE ANALYSIS

TOTAL COMPETITIVE ANALYSIS
TABLE 28 TOTAL COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION AND ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 ($ MILLIONS/%)
FIGURE 16 TOTAL COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION AND ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%)
DEPRESSION COMPETITIVE ANALYSIS
TABLE 29 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 ($ MILLIONS/%)
FIGURE 17 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%)
TABLE 30 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY THE TOP FOUR DRUG MANUFACTURERS’ MARKET SHARE, 2008 ($ MILLIONS/%)
FIGURE 18 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY THE TOP FOUR DRUG MANUFACTURERS’ MARKET SHARE, 2008 (%)
ANTIANXIETY COMPETITIVE ANALYSIS
TABLE 31 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 ($ MILLIONS/%)
TABLE 32 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY THE TOP FOUR DRUG MANUFACTURER MARKET SHARE, 2008 ($ MILLIONS/%)
FIGURE 19 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%)
FIGURE 20 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY THE TOP FOUR DRUG MANUFACTURER MARKET SHARE, 2008 (%)

Chapter-7: PATENT ANALYSIS

TABLE 33 SELECTED MANUFACTURER PATENTS FOR TREATMENT OF DEPRESSION AND ANXIETY

Chapter-8: COMPANY PROFILES

ASTRAZENECA
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 34 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
BRISTOL-MYERS SQUIBB COMPANY
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 35 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
DOV PHARMACEUTICAL, INC.
BRIEF HISTORY
PRODUCTS
RESEARCH AND DEVELOPMENT
ELI LILLY & COMPANY
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 36 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
FABRE-KRAMER PHARMACEUTICALS, INC.
BRIEF HISTORY
PRODUCTS
RESEARCH AND DEVELOPMENT
FOREST PHARMACEUTICALS, INC.
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 37 COMPANY REVENUES, 2007 AND 2008 ($ BILLIONS)
RESEARCH AND DEVELOPMENT
GLAXOSMITHKLINE
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 38 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
JAZZ PHARMACEUTICALS, INC.
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 39 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
JOHNSON & JOHNSON
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 40 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
H. LUNDBECK A/S
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 41 COMPANY REVENUES 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
MERCK & COMPANY, INC.
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 42 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
PFIZER, INC.
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 43 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
ROCHE, INC.
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 44 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
SANOFI-AVENTIS
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 45 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
SEPRACOR, INC.
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 46 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
SCHERING-PLOUGH CORP
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 47 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT
WYETH
BRIEF HISTORY
PRODUCTS
COMPANY REVENUE HISTORY
TABLE 48 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS)
RESEARCH AND DEVELOPMENT

Chapter-9: APPENDIX

APPENDIX A
ALTERNATIVE APPROACHES TO MENTAL HEALTH ORGANIZATIONS
APPENDIX B
COMPANY LISTINGS
TABLE 49 COMPANY LISTINGS